Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.66 |
| ▸ | CCR3 | P51677 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2976109 | 0.98 | ACHE (0.64) | ACHECCR3SIGMAR1OPRM1DRD2 | |
| SCHEMBL3965861 | 0.91 | RECQL (0.59) | ACHECCR3SIGMAR1OPRM1DRD2 | |
| SCHEMBL1911332 | 0.90 | LTA4H (0.60) | ACHECCR3SIGMAR1OPRM1DRD2 | |
| SCHEMBL13024536 | 0.90 | LTA4H (0.60) | ACHECCR3SIGMAR1OPRM1DRD2 | |
| SCHEMBL13634431 | 0.90 | LTA4H (0.60) | ACHECCR3SIGMAR1OPRM1DRD2 | |
| SCHEMBL28173289 | 0.88 | ACHE (0.64) | ACHECCR3SIGMAR1OPRM1DRD2 | |
| SCHEMBL5570638 | 0.86 | ACHE (0.62) | ACHECCR3SIGMAR1OPRM1DRD2 | |
| SCHEMBL19311894 | 0.86 | ACHE (0.62) | ACHECCR3SIGMAR1OPRM1DRD2 | |
| SCHEMBL21375648 | 0.85 | SIGMAR1 (0.60) | ACHECCR3SIGMAR1OPRM1DRD2 | |
| SCHEMBL3311545 | 0.85 | ACHE (0.60) | ACHECCR3SIGMAR1OPRM1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2479165-B1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-2643332-B1 | METHOD FOR BUFFERING A CHEMICAL OR BIOLOGICAL COMPOSITION | SACHEM INC (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2643332-A2 | METHOD FOR BUFFERING A CHEMICAL OR BIOLOGICAL COMPOSITION | Sachem, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| US-8361779-B2 | Buffer compounds | SACHEM, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2012071102-A2 | BUFFER COMPOUNDS | SACHEM, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129240-A1 | BUFFER COMPOUNDS | SACHEM, INC. | 2012-05-24 | — | — | US | disclosed |
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| WO-2011162515-A2 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHD3ITION OF TYROSINE KINASE ACTIVITY | HANMI HOLDINGS CO. , LTD. (KR) | 2011-12-29 | — | — | WO | disclosed |
| WO-2004104001-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
| EP-0823906-B1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20010039286-A1 | 2-aryl indole derivatives and their use as therapeutic agents | DINNELL KEVIN (GB) | 2001-11-08 | — | — | US | disclosed |
| US-5981520-A | USEFUL FOR TREATING ASTHMA, BRONCHOSPASM, ALLERGIES, ANXIETY, COUGHING OR PAIN | SCHERING CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| US-5795894-A | TREATMENT OF ASTHMA AND BRONCHOSPASM | SCHERING CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0823906-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034864-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-11-07 | — | — | WO | disclosed |
| EP-0309043-B1 | Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides | JANSSEN PHARMACEUTICA NV (BE) | 1994-11-09 | — | — | EP | disclosed |
| US-3980788-A | XANTHENYL COMPOUNDS | SMITHKLINE CORPORATION (US) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | ACHE 314/4885CCR3 89/4885SIGMAR1 688/4885 |
| US-20010039286-A1 | 2-aryl indole derivatives and their use as therapeutic agents | IDO1, IDO2, CNR2 | ACHE 107/4885CCR3 358/4885SIGMAR1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.